1AD AdAlta Ltd
- 0.029
- +0.001+3.57%
AdAlta Ltd News
AdAlta Ltd. Expands Investment and Partnerships
AdAlta Ltd. Seeks ASX Expansion With New Securities
AdAlta Ltd Hosts Investor Webinar on Growth Funding
AdAlta Secures Up to AU$3.7 Million for MOU, I-body Programs
AdAlta (ASX:1AD) has secured up to AU$3.7 million from New Zealand Life Sciences Capital and Meurs Investment to accelerate its recent memorandum of understanding with SYNthesis BioVentures and to pro
AdAlta Ltd Secures Loan Repayment Extension
AdAlta Ltd. Raises $3.7 Million for Strategic Growth
AdAlta Ltd. Advances Fibrosis Treatment, Secures Funding
AdAlta Ltd Expands Securities on ASX
AdAlta Ltd Announces Option Exercise Opportunity
AdAlta Ltd Advances Cellular Immunotherapy Innovations
AdAlta Explores Cancer Immunotherapies Joint Venture for Western Market
AdAlta (ASX:1AD) signed a memorandum of understanding with SYNthesis BioVentures Fund to provide innovative cellular immunotherapies from Asia to the Western market through a joint entity, according to a Monday filing with the Australian bourse.
AdAlta Ltd: Pioneering Next-Gen Cancer Immunotherapies
AdAlta's AD-214 Demonstrates Safety and Efficacy Potential for Fibrotic Disease Treatment
Top-line results from a Phase I extension study of AdAlta’s (ASX: 1AD) lead asset AD-214 in the treatment of fibrotic disease have established the safety, tolerability and bioavailability of a target dose for planned Phase II clinical studies.
Stocks of the Hour: Atomo Diagnostics, AdAlta, Aruma Resources
To register for Friday's webinar click here.Atomo Diagnostics (ASX:AT1) has announced securing purchase orders from Viatris Healthcare Pty Ltd for approximately AUD $970,000 worth of HIV Self-Tests, m
AdAlta-La Trobe University Collab Discovers New I-Bodies for Malaria Treatment; Shares Climb 4%
AdAlta's (ASX:1AD) research collaboration with La Trobe University discovered a new family of i-bodies that protect cells from invasion by malaria and related parasites, the drug development firm said Tuesday.
Adalta Posts Upbeat Results From Phase I Trial of Fibrotic Disease Drug
Adalta (ASX:1AD) announced the interim results of the phase I extension clinical study of its AD-214 drug, being developed to treat fibrotic diseases, saying the results "reinforce the safety profile
It's Probably Less Likely That AdAlta Limited's (ASX:1AD) CEO Will See A Huge Pay Rise This Year
AdAlta Raises AU$1.7 Million Via Oversubscribed Placement; Shares Down 9%
Drug developer AdAlta (ASX:1AD) raised AU$1.7 million via an oversubscribed placement priced at AU$0.02 per share. Proceeds will fund the completion of phase one extension clinical study of AD-214 and
AdAlta to Seeks AU$1.2 Million From Share Placement
AdAlta (ASX:1AD) is looking to raise up to AU$1.23 million from the placement of 61.5 million new shares to professional investors at AU$0.02 apiece, a Thursday filing said. The investors will also be
AdAlta Receives AU$2.4 Million R&D Tax Rebate
AdAlta (ASX:1AD) received a research and development tax incentive refund of AU$2.4 million. Also, the drug developer extended the terms of its AU$4.0 million loan facility, which is part of the Victo
Analysis
Price Target
No Data
